Chaperon Submits Securities Registration Statement... Full-Scale Entry into Initial Public Offering

September 20-21 Demand Forecast, September 26-27 Subscription

[Asia Economy Reporter Lee Gwan-ju] Shaperon, which passed the preliminary review for listing on KOSDAQ, submitted a securities registration statement to the Financial Supervisory Service on the 12th and is officially pushing forward with its initial public offering (IPO).

Shaperon plans to offer a total of 2,747,000 shares, with a desired offering price band of 8,200 to 10,200 KRW per share, aiming to raise up to 28 billion KRW through this offering.

From the 20th to 21st of next month, demand forecasting will be conducted targeting institutional investors to finalize the offering price, followed by subscription on the 26th and 27th, with plans to list on KOSDAQ within the year. The lead underwriter is NH Investment & Securities, and all offered shares will be newly issued without any sale of existing shares. Existing shareholders have voluntarily imposed lock-ups on the majority of their holdings, resulting in over 70% of shares being under post-listing lock-up protection.

The funds raised will be used for research and development, facility investment, and operating expenses. In particular, the company plans to focus on strengthening the competitiveness of each pipeline through global clinical development, discovering new pipelines, securing excellent researchers and research facilities, and promoting global commercialization.

Seong Seung-yong and Lee Myung-se, co-CEOs of Shaperon, emphasized, “Through this listing, we will focus on pipeline development to generate stable profits and strive to maximize corporate value and competitiveness based on new drug development achievements.”

This content was produced with the assistance of AI translation services.